GlassScriptPhysician profile
James Denis O'Hare
NPI 1932526878
$3,985.89
in general payments reported to CMS, 2019-2025
35 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2022: $299 · 2023: $867 · 2024: $1,228 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.21 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $555.99 | 2024-2025 | Tepezza, Prolia, Repatha |
| Novo Nordisk INC | $458.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $372.80 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $324.01 | 2019-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $188.88 | 2023-2025 | Yorvipath |
| Abbott Laboratories | $188.69 | 2022-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $179.37 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $165.59 | 2022-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $144.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Madrigal Pharmaceuticals | $137.49 | 2025 | Rezdiffra |
| Nevro Corp. | $127.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $106.01 | 2023-2025 | |
| Medtronic, INC. | $92.60 | 2023-2025 | Minimed 780g, Guardian Connect |
| Bayer Healthcare Pharmaceuticals INC. | $84.83 | 2024-2025 | |
| Mannkind Corporation | $82.14 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $75.22 | 2025 | Cequr Simplicity |
| Acella Pharmaceuticals, LLC | $66.59 | 2023 | NP Thyroid 60 |
| Insulet Corporation | $64.44 | 2024-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $60.61 | 2023-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $58.80 | 2024-2025 | |
| Glaxosmithkline, LLC. | $51.86 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $48.22 | 2024-2025 | Cologuard Collection Kit |
| Beta Bionics, INC. | $48.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tolmar, INC. | $38.29 | 2023-2025 | Jatenzo |
| Horizon Therapeutics Plc | $35.97 | 2022-2023 | Tepezza |
| Averitas Pharma INC. | $33.24 | 2023 | Qutenza |
| Amryt Pharma Holdings LTD | $31.37 | 2023 | Mycapssa |
| Neurelis, INC. | $25.62 | 2023 | Valtoco |
| Recordati_rare_diseases_inc. | $23.50 | 2024 | Isturisa, Signifor Lar |
| Sequel Med Tech, LLC | $22.45 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $21.78 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.09 | 2025 | Strensiq |
| Eisai INC. | $18.52 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.93 | 2023 | Nuedexta |
| Mylan Specialty L.P. | $15.12 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James O'Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.